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Abstract
Background: At the DKMS Life Science Lab, Next Generation Sequencing (NGS) has been used for ultra-high-
volume high-resolution genotyping of HLA loci for the last three and a half years. Here, we report on our
experiences in genotyping the HLA, CCR5, ABO, RHD and KIR genes using a direct amplicon sequencing approach
on Illumina MiSeq and HiSeq 2500 instruments.
Results: Between January 2013 and June 2016, 2,714,110 samples largely from German, Polish and UK-based potential
stem cell donors have been processed. 98.9% of all alleles for the targeted HLA loci (HLA-A, -B, -C, -DRB1, -DQB1
and -DPB1) were typed at high resolution or better. Initially a simple three-step workflow based on nanofluidic chips in
conjunction with 4-primer amplicon tagging was used. Over time, we found that this setup results in PCR artefacts
such as primer dimers and PCR-mediated recombination, which may necessitate repeat typing. Split workflows for
low- and high-DNA-concentration samples helped alleviate these problems and reduced average per-locus
repeat rates from 3.1 to 1.3%. Further optimisations of the workflow included the use of phosphorothioate
oligos to reduce primer degradation and primer dimer formation, and employing statistical models to predict
read yield from initial template DNA concentration to avoid intermediate quantification of PCR products.
Finally, despite the populations typed at DKMS Life Science Lab being relatively homogenous genetically, an
analysis of 1.4 million donors processed between January 2015 and May 2016 led to the discovery of 1,919
distinct novel HLA alleles.
Conclusions: Amplicon-based NGS HLA genotyping workflows have become the workhorse in high-volume
tissue typing of registry donors. The optimisation of workflow practices over multiple years has led to insights
and solutions that improve the efficiency and robustness of short amplicon based genotyping workflows.
Keywords: Next generation sequencing, HLA genotyping, High resolution, High throughput, Amplicon PCR,
DKMS, Primer dimers, PCR chimerism, Novel alleles
Background
The hyperpolymorphic human leukocyte antigen (HLA)
system, spanning about 4 Mb on the short arm of chromo-
some 6, contains a number of genes that play key roles in
the adaptive immune response [1]. Especially the “classical”
HLA genes encoding the 6 major antigen-presenting pro-
teins (HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1) play a
crucial role in solid organ and haematopoietic stem-cell
transplantation (HSCT), where outcome is mostly deter-
mined by the genetic concordance of HLA alleles between
donors and recipients [2]. With more than 16,000 allelic
variants identified today (http://www.ebi.ac.uk/ipd/imgt/
hla/stats.html), combinatorial diversity in this region ex-
plodes, and the search for a matching unrelated donor can
resemble the search for the proverbial needle in a haystack.
Despite 29 million potential unrelated donors for
patients in need of an allogenic HSCT being currently
registered worldwide (https://www.wmda.info), finding
suitably matched donors can be severely hampered by
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the heterogeneous quality of the available genotyping in-
formation [3]. Until recently, unrelated stem-cell donor
registries all over the world, which provide the bulk of
this information, have utilised different serological and
DNA-based HLA typing methods with variable resolution,
such as sequence-specific oligonucleotide probes (SSOP),
sequence-specific primer (SSP) PCR, or sequence-based
typing (SBT) using Sanger sequencing.
However, these technologies are limited in throughput,
precision and achievable coverage when compared to
next generation sequencing (NGS)-based HLA typing
methods [4]. Benefits of NGS-based typing approaches
include high throughput through massive parallelisation,
clonal sequencing of single molecules, sample multiplex-
ing, and reduced costs per sample [5]. Whilst the exten-
sive allelic diversity of HLA class I and II genes has
made, and continues to make, high-resolution HLA typ-
ing challenging, the advances in NGS technologies have
made ultra-high-throughput, cost-effective and precise
HLA typing possible at an unprecedented scale [5–7].
To date, DKMS hosts HLA genotyping data for 7 mil-
lion registered donors across Germany, Poland, the UK
and the USA. Currently all DKMS samples from newly
recruited donors are typed at the high-throughput geno-
typing facility DKMS Life Science Lab in Dresden,
Germany. As of 2013, DKMS Life Science Lab success-
fully replaced a Sanger SBT workflow with a NGS HLA-
typing workflow, initially based on Illumina MiSeq and
later Illumina HiSeq 2500 amplicon sequencing [5].
Rapid advances in laboratory automation and increasing
sequencing capacity have led to a dramatic growth from
30,000 donor samples processed every month to cur-
rently over 110,000 samples per month over the last
three and a half years (Fig. 1). The total number of
donor samples typed by NGS surpassed 2.7 million sam-
ples in June 2016 (Fig. 1), whilst the costs for HLA geno-
typing have dropped by more than 50% as compared to
Sanger-based sequencing.
NGS technologies also make it easier to adapt read
coverage to the experimental demand at minimal in-
creases in cost. This results in an opportunity to expand
the donor genotyping profile with ease and cost effect-
iveness by adding genes of interest that either may im-
pact clinical outcome after HSCT (e.g., the KIR gene
family), or that provide additional information to clini-
cians selecting the best possible donor (e.g., blood group
markers, CCR5). Consequently, these markers were
gradually added to the DKMS typing profile, starting
with CCR5, ABO and RHD as of 2014 and followed by
KIR genes as of 2015.
Using NGS technologies in a highly automated, high-
volume production environment with high demands on
data quality provides a number of key benefits over trad-
itional Sanger sequencing and enables routine typing
operations at an unprecedented scale. At the same time
NGS poses a number of novel challenges and introduces
complexities of its own. Here, we report on our experi-
ences of using amplicon-based HLA typing by NGS at a
massive scale. We present not only the performance
metrics of our NGS-based typing approach but also key
lessons we learned over a time period of three and a half
years typing 2.7 million donors for six HLA loci.
Results
High throughput at high resolution
Between January 1, 2013 and June 30, 2016 a total of
2,714,110 samples were processed by amplicon-based
NGS HLA typing first on the Illumina MiSeq platform
until August 2014, and from then on predominantly on
the HiSeq 2500 platform [5]. The move from MiSeq to
HiSeq 2500 was driven by capacity demands and Illu-
mina providing the “Rapid Run Mode” with 2×250 bp
read lengths. The initially available read length of 2×125
bp on the HiSeq had not allowed for full coverage of the
exons for our direct amplicon sequencing approach.
Since October 2013, 2,245,143 donors have additionally
been typed for CCR5 and the blood groups ABO and RHD
[8]; since October 2014 1,208,368 donors have additionally
been typed for the presence/absence of KIR genes (Fig. 1).
The monthly throughput during the first year (2013)
ranged from 14,862 to 56,493 (average 29,828) donor
samples; this throughput then increased ranging from
57,294 to 90,316 (average 70,095) samples across 2014
and 2015, and increased further in 2016 ranging from
99,094 to 133,746 (average 112,358) samples (Fig. 1).
Based on data from the HLA core exons 2 and 3, be-
tween 96.78% (HLA-C) and 99.97% (HLA-DPB1) of the
samples could be typed at high resolution or better as
defined by EFI standard v6.3 (http://www.efiweb.eu/),
with the exception that null alleles caused by a mutation
outside of exons 2 and 3 remain unidentified (Table 1).
For the remainder of the samples intermediate typing
resolutions were obtained, with the exception of 21 low-
resolution HLA-B samples (Table 1).
Source material variability
For the vast majority (82%) of samples DNA is extracted
from buccal cells. Donors are provided with two nylon
DNA-sampling swabs (FLOQSwabs™ hDNA free, Copan
Italia Spa, Brescia, Italy) and instructions to scrape the
inside of the cheek with the swabs firmly for 30 s.
These self-administered swabs are subsequently
mailed to DKMS Life Science Lab for DNA extraction
and genotyping.
DNA concentrations achieved by extracting from buc-
cal samples have varied over a wide range. Ninety per-
cent of all extractions yielded between 4.8 ng/μl and
86.1 ng/μl of DNA (median 26.6 ng/μl, N = 1,941,300).
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In addition, we observed marked fluctuations in median
DNA concentrations over the complete time period and
a strong dependence on sample provenance (Fig. 2).
Buccal samples derived from UK donors generally
yielded lower DNA concentrations (median 18.7 ng/μl
[90% central range 3.9 to 62.7 ng/μl]) than samples de-
rived from donors in Poland or Germany (median 33.5
and 26.5 ng/μl [90% central range 5.5 to 101.0 and 4.8 to
83.7 ng/μl], respectively). The reason for this discrep-
ancy is unclear but might reflect differences in compli-
ance, sample envelope material or sample transit time.
No significant seasonal effects were detected.
It is possible that the large variability in the obtained
DNA concentration is at least partially driven by differ-
ences in compliance with swabbing instructions by
donors. For instance, a concerted effort in 2015Q1 by
DKMS Polska emphasising the importance of the sam-
pling procedure appears to have caused a dramatic in-
crease in DNA yield from median 25.3 ng/μl (90%
central range 3.6 to 92.6 ng/μl) before 2015 to 40.1 ng/μl
(90% central range 8.5 to 105.1 ng/μl) in 2015 and 2016.
At least for Fluidigm-based workflows, DNA concen-
trations lower than 2 ng/μl have been found empirically
to compromise genotyping results severely. Overall,
0.94% of all samples fell below this threshold, but the
prevalence of such low-quality samples varied over time
and with sample provenance (Additional file 1: Figure S1).
These cases warrant a second extraction attempted using
the alternative swab provided by the donor. Unfortunately,
the first DNA extraction is a very good predictor of
DNA concentrations obtained from the second swab
(Pearson’s correlation, r = 0.79, n = 99,677, Additional file 2:
Figure S2). Only 56.5% of the samples with an initial DNA
concentration lower than 2 ng/μl achieved a DNA concen-
tration higher than 2 ng/μl using the second swab. Since
there was a 26-day period (90% central range 6 to 51 days)
between the first and second extraction attempt, one
may argue that the prolonged storage of swabs may
have adversely affected DNA yield. However, samples
with higher initial DNA concentration also tend to
yield high concentrations in a second extraction
(Additional file 2: Figure S2). This reinforces the notion
that, to a large extent, individual patterns of compliance
impact the yield from DNA extractions.
Table 1 NGS genotyping resolution for six HLA loci in 2.7
million DKMS donors
Resolution
Locus Number of samples High [%]a Intermediate [%] Low [%]
HLA-A 2,710,959 99.60 0.40 0
HLA-B 2,708,617 98.13 1.87 0.001
HLA-C 2,706,849 96.78 3.22 0
HLA-DRB1 2,710,549 99.92 0.08 0
HLA-DQB1 2,710,553 98.82 1.18 0
HLA-DPB1 2,706,356 99.97 0.03 0
anull alleles caused by a mutation outside of exons 2 and 3
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Fig. 1 Cumulative and monthly numbers of donor samples genotyped at the DKMS Life Science Lab since 2013 as part of routine operations.
The grey line shows the total cumulative number of genotyped samples, the coloured lines show gene-specific cumulative numbers; grey-shaded
bars indicate monthly throughput. Black horizontal bars show (bi-)yearly mean throughput. The y-axis is square root scaled to enhance readability
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Read quality
High-quality and unbiased sequence read data obtained
from the sequencing platform greatly facilitate accurate
and reproducible high-throughput typing. For Illumina in-
struments, the two common metrics for overall run per-
formance are the number of reads passing filter (PF reads),
i.e., reads that pass an internal quality filtering procedure
(chastity filter), and the total percentage of bases that are
assigned a Phred quality score of 30 (99.9% accuracy) or
better (%Q30). The density of clonal clusters on Illumina
flow cells is expected to strongly influence overall perform-
ance. By increasing the cluster density the read yield is in-
creased until too many clusters are so close that they
cannot be separated algorithmically. At this point, read
yield saturates and may even decline and, according to Illu-
mina documentation, sequencing quality may suffer. Illu-
mina suggests optimal ranges of cluster densities and the
corresponding expected outputs for different sequencing
chemistries and instruments (compare Fig. 3). Achieving a
designated cluster density requires loading the correct
amount of high-quality library DNA onto the flow cells.
Special considerations, however, apply for sequencing
from low-diversity libraries such as libraries generated
from amplicons. Diverse or balanced libraries (e.g., librar-
ies generated from random fragments) show an approxi-
mately equal distribution of all four nucleotides in every
cycle. The Illumina RTA (Real Time Analyzer) software
originally was optimised using balanced libraries to accur-
ately locate cluster coordinates during the first sequencing
cycles (template generation). Amplicon-based libraries, in
contrast, tend to show a biased nucleotide distribution
which may lead to a failure to segregate adjacent clusters
and can adversely affect yield as well as data quality. Even
though recent RTA versions have been optimised to be
more robust with regard to low-complexity libraries,
Illumina still recommends spiking in 5-10% PhiX for
increasing diversity and targeting a more conservative
cluster density.
For our NGS-based routine typing operations we have
thus far performed a total of 3,642 runs distributed
across two Illumina platforms (3,331 runs on MiSeq in-
struments, 311 runs on HiSeq 2500 instruments) and 3
versions of sequencing chemistry (MiSeq reagent kit v2,
1621 runs; MiSeq reagent kit v3, 1710 runs; and HiSeq
Rapid Run SBS Kit v2, 311 runs). Whilst we initially
tried to attain the cluster densities supported for
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Fig. 2 Quarterly average concentration of donor DNA extracted from buccal cells. Panels present differences between Germany (DE), Poland (PL)
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balanced libraries it quickly became clear that our low-
diversity HLA libraries required a reduction in template
input for optimal yield and data quality (Fig. 3). This ef-
fect was especially noticeable early on for the MiSeq v2
chemistry where a number of runs showed reduced PF
read counts at supported cluster densities or higher
(Fig. 3, upper panel). With MiSeq v3, less data degrad-
ation was observed at the supported cluster densities but
the strategy to undercluster was retained since optimal
yield was readily achieved even at lower densities (Fig. 3,
middle panel). HiSeq flow cells with Rapid Run SBS v2
chemistry could safely be clustered at the supported
upper limit of 1,000 k/mm2 without sacrificing a linear
increase in yield at all (Fig. 3, lower panel). Interestingly,
no obvious relationship between achieved cluster dens-
ities and %Q30 became apparent in our runs. The most
likely explanation for amplicon libraries performing
markedly better on MiSeq v3 and especially the HiSeq is
that new versions of the RTA software were rolled out
by Illumina with algorithmic improvements to better
cope with low-diversity libraries.
A critical factor influencing data quality and yield are
template-independent primer-primer interactions that
take place during the PCR steps and give rise to artificial
products, especially primer dimers (PDs) [9]. Although
primer dimer formation can be reduced by careful
primer design and the application of stringent PCR con-
ditions, it becomes increasingly difficult to avoid all pri-
mer interactions when developing multiplexed reactions.
For the Fluidigm workflow, before the split of low-
concentration and high-concentration samples into sep-
arate workflows, we experienced average monthly PD
rates ranging from 34.0% ± 14.5% SD in January 2014 to
4.5% ± 1.9% SD in November 2015. Average monthly PD
rates were independent of sequencing instrument and/or
chemistry (two-way ANOVA, F2,35 = 1.76, P = 0.19) but
decreased significantly over time due to continuous
process optimisations and tweaking of the primers used
in routine operations (two-way ANOVA, F24,35 = 46.3,
P < 0.001, Additional file 3: Table S1).
A particularly troublesome source of increased PD for-
mation was identified after a careful analysis of the se-
quences of primer dimer products. It showed that the
primer sequences involved exhibited recurring patterns
of degradation at their 3’-ends. We tracked the cause to
the hot-start PCR system used (Roche FastStart High Fi-
delity PCR System). In contrast to the documentation’s
claim of “inactivity at low temperatures”, only the poly-
merase activity is minimised at ambient temperatures by
the hot-start modifications. The 3’-exonuclease providing
the proofreading capabilities is not modified to require
heat activation. As a consequence, the 3’-exonuclease de-
grades primers at the 3’-end in the reaction mix during
cooled storage and reaction setup. A change in protocol
was therefore applied during May/June 2015 where stand-
ard primers were replaced by modified primers incorpor-
ating three phosphorothioated nucleotides at the 3’-end to
inhibit exonuclease degradation (PTO primers). Prior to
this protocol change we observed an average PD rate of
17.0% (±8.6%, n = 59,534, April 2015). After the protocol
change was fully implemented the average PD rate
dropped to 6.4% (±2.6%, n = 62,695, July 2015).
The PD problem was further exacerbated by a peculi-
arity of our amplification protocol: In a standard PCR
setup, PDs derived by 3’-end degradation are expected
to form an inefficient substrate for amplification in sub-
sequent PCR cycles as the majority of primers continue
to carry intact 3’-ends and fail to bind to the degraded
PDs. In contrast, with the 1-PCR 4-primer approach
used in our Fluidigm workflow, we use two inner
primers with target-specific 3’-tails and a 5’-tail comple-
mentary to two outer indexing primers [5]. Thus, PDs
formed by the inner primers constitute an appropriate
substrate for further amplification by the outer primers
in subsequent cycles.
The notion that the 1-PCR 4-primer (Fluidigm) proto-
col increases the risk of PD formation was also sup-
ported by a significant reduction in PD rates after the
alternative 2-PCR 2-primer (384 PCR) protocol was
introduced for low-DNA-concentration samples in
November 2015 (Fluidigm: 3.25% ± 0.98% PD rate; 384
PCR: 0.9% ± 0.3% PD rate; two-way ANOVA, F1,13 = 36.7,
P < 0.001). The move from the 1-PCR 4-primer setup to
the 2-PCR 2-primer setup is confounded by a commen-
surate move from the Fluidigm nanofluidics platform to
standard 384-well plates with significantly larger reaction
volumes and consequently different reaction kinetics.
However, the KIR genes were always amplified on plates.
To tease apart the relative contributions of PCR protocol
and reaction volume, we analysed different HLA and
KIR amplicons separately (Additional file 4: Figure S3).
Disregarding amplicons with negligible PD rates (<0.1%)
and an extreme outlier (HLA-A exon 2, Additional file 4:
Figure S3), the remaining 6 HLA and 3 KIR amplicons
had similar decreases in average PD rates when moving
from a 1-PCR 4-primer approach to a 2-PCR 2-primer
setup (-86.0% ± 19.5% for HLA, -86.6% ± 15.2% for KIR).
This suggests that there is no correspondence between re-
action volume and the degree of primer dimerisation.
High proportions of primer dimers not only reduce
the number of reads on target per sample but also influ-
ence overall run quality by lowering %Q30 (Fig. 4, linear
model, average reduction %Q30 = -3.4% ± 0.004% per 10%
increase in PD rate, t1452986 = - 924.3, P < 0.001). This is
probably explained by the fact that we are sequencing more
cycles than the average length of the primer dimers
whereby the polymerase runs off the template and pro-
duces low-quality data for the remaining sequencing cycles.
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Independent of primer design and PCR conditions, we
also found template DNA concentration to influence
primer dimer rates within the nanofluidic Fluidigm
workflow. At DNA concentrations below 30 ng/μl we
observed a steep rise in the average PD rate, whereas the
PD rate remained relatively constant at higher concentra-
tions (Fig. 5). Whilst low target copy numbers have been
reported before as favouring primer oligomerisation and
mispriming [10], this effect appears to be exacerbated on a
nanofluidics platform. When the 384 PCR workflow was
introduced for low-concentration samples in November
2015, we observed an overall marked decrease in PD
rate in this workflow (discussed above, Fig. 5). Inde-
pendent of this effect, however, both the Fluidigm workflow
(linear model, t9998 = -31.3, P < 0.001) and the 384 PCR
workflow (linear model, t9998 = -15.4, P < 0.001) showed
Fig. 4 Average percentage of bases reaching a quality score of 30 or higher per run (± SD) vs. proportion of primer dimers (binned into 10% intervals)
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Fig. 5 Dependency of primer dimer rate from initial DNA concentration and workflow. The two workflows differ both in their reaction volumes
and amplification strategies (Fluidigm: single PCR, 4 primers; 384 PCR: 2 PCRs, 2 primers each). Solid lines depict generalised additive model fits
using a cubic penalised regression spline. The shaded bands around the regression lines indicate the pointwise 95% confidence intervals on the
fitted values
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significant rates of increase in PDs with decreasing DNA
concentrations (based on 10,000 samples drawn randomly
from each workflow with DNA concentrations of less than
18 ng/μl). The magnitude of the effect was slightly, albeit
significantly, larger in the Fluidigm workflow with an esti-
mated 3.4% (95% CI = 3.2%–3.6%) change in PD rate for
each ng/μl DNA less compared to the 384 PCR work-
flow with an estimated 2.7% (95% CI = 2.3%–3.0%)
change in PD rate for every ng/μl DNA reduction.
We conclude that we were able to reduce the PD rate
from 17% to less than 1% mainly by (a) using PTO-
modified primers to avoid degradation and (b) moving
from a 1-PCR 4-primer setup to a more conventional
2-PCR setup for target-specific amplification and bar-
coding PCR. Given the strong effect on overall run
quality, monitoring and minimising PD rates seems
highly advisable when performing amplicon-based NGS
experiments.
Read artefacts
In addition to primer dimer formation, amplicon-based
sequencing is subject to another frequent methodo-
logical pitfall, namely the PCR-mediated formation of
cross-over products between the two allelic variants, also
called PCR chimerism [11, 12]. These reads incorporate
portions of both alleles present in the sample into a sin-
gle sequence, forming recombinants between the start-
ing templates. Chimeras are more likely to be observed
with increasing numbers of PCR cycles and if the initial
concentration of templates is high [13]. Such cross-over
events can be filtered by our analysis software as long as
the parent sequences are not significantly outnumbered
by the recombinant sequences. In addition, chimeras
combining target and off-target reads stemming from,
for instance, HLA-DRB3/4/5 or HLA-H are especially
challenging to detect. High rates of chimeric reads can
therefore confound the ability to successfully call the
correct alleles [5].
The observed rate of chimeras depends heavily on the
amplified locus and exon (Fig. 6; Fluidigm workflow,
one-way ANOVA, F11,3683 = 82.5, P < 0.001; 384 PCR
workflow, one-way ANOVA, F11,1754 = 55.2, P < 0.001).
HLA-C exon 3 consistently shows the largest average
proportion of chimeras amongst on-target reads (median
15.2%; IQR 4.6 to 23.6%), whilst HLA-DPB1 exon 3 and
HLA-DRB1 exon 3 rarely show any sign of chimeric reads.
The low chimerism rates observed for exon 3 of these
class II HLA genes is possibly explained by the fact that
the currently known exon 3 allelic sequences exhibit little
variability, which facilitates escaping chimerism detection.
As with the other aforementioned metrics of quality,
we observed a dramatic reduction in cross-over rates for
the 384 PCR workflow (Fig. 6, linear model, average re-
duction in chimeric reads = -36.6% ± 1.2%, t5437 = -30.4,
P < 0.001). This seems counterintuitive given that the
Fluidigm workflow has fewer amplification cycles com-
pared to the 384 PCR workflow (35 cycles and two steps
of 35 and 10 cycles, respectively).
However, it has been observed that chimera formation
largely occurs at late PCR cycles [14, 15] and is also pro-
moted by higher initial template concentration [13]. In
the Fluidigm PCR reactions initial template DNA con-
centrations are much higher (at least 8.8 ng/μl in an
11 nl reaction volume) than in the 384 PCR reactions (at
most 2.7 ng/μl in a 10 μl reaction volume). This is to en-
sure that sufficient product for downstream processing
is generated in the much smaller reaction volumes on
Access Array chips. Unfortunately, as these reactions
now reach saturation earlier they also offer more oppor-
tunities for crossing-over at earlier cycles [13].
Quantification-free post-PCR normalisation
Ideally, each PCR product should be quantified individu-
ally and subsequently pooled equimolarly. However, to
keep the workflow simple and cost-effective we opted to
pool PCR products without attempting to normalise
DNA concentrations.
As data from samples amplified on Fluidigm Access
Array chips accumulated, we found a weak but signifi-
cant relationship between initial DNA concentration and
the final number of reads generated for a sample (Fig. 7,
left panel). Initial DNA concentration Ci and final num-
ber of reads per sample R show a saturation dependency
that can be modelled by a Michaelis-Menten equation:
R ¼ Ci= Ci þ Kmð ÞRmax
Fitting a two-parameter Michaelis-Menten model to
the available data allowed for estimating the Michaelis-
constant, Km, and the maximum achievable read num-
ber, Rmax, for our system. Thus, we could use the overall
Km estimate to predict relative final read counts for sam-
ples processed on an Access Array chip and adjust the
amount of PCR product entering the post-PCR pool to
minimise the effect of differences in DNA concentra-
tions. Implementing this quantification-free post-PCR
normalisation strategy balanced read coverage further
across a wide range of initial DNA concentrations (Fig. 7,
right panel). Only samples with DNA concentrations of
less than 5 ng/μl yield too little PCR product to enable
complete compensation.
Read coverage
For reliable genotyping it is advantageous not only to
achieve a balanced depth of coverage across samples but
also across amplicons. Analysing 468,305 donor samples
distributed over 299 MiSeq/HiSeq runs performed be-
tween January 2016 and June 2016, on average 56,200
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(interquartile range [IQR] 44,560–69,690) reads were
produced per sample. Of these reads, 95.8% (IQR 94.3–
96.8%) mapped to their respective target amplicons and
could be used for subsequent analyses. These reads par-
tition into those targeting HLA loci (median 19,463;
IQR 14,586–25,695), KIR loci (median 25,415; IQR
18,617–33,406), and others (CCR5 and blood groups
ABO and RHD; median 6,127; IQR 4,178–9,943).
The number of on-target reads for individual HLA
amplicons varied across loci and exons (Fig. 8; two-way
ANOVA, F11, 49726 = 468.3, P < 0.001). Across amplicons
we obtained a median coverage ranging from 867-fold
(HLA-DQB1, exon 2) to 2034-fold (HLA-A, exon 2).
However, the relative read counts across amplicons have
also changed over time as primers were tweaked to try
to equalise read counts as much as possible (two-way
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ANOVA, F5, 49726 = 13.1, P < 0.001). Uneven read depths
across amplicons are due to different primer efficiencies
and amplification biases where some sequences tend to
amplify better than others [16]. Different primer efficien-
cies can be alleviated by tweaking either the primer se-
quence itself or by adjusting the relative amount of
primer added to the PCR reaction, with the former being
undertaken after the initial primer design. Unfortunately,
it turns out that some degree of adjusting the relative
amount of primer may become necessary when new
batches of reagents are put into use (approximately once
per month). However, despite perfectly adjusted primer
sets, sample-to-sample variations (for example, in con-
centration and purity) resulted in diverging amplification
kinetics and varying endpoints. Therefore, only post-
PCR quantification and normalisation would deliver fully
balanced amplicons. Costs for such a quantification step
for each amplicon would increase current sequencing
costs several fold. The low cost of sequencing allowed us
to bypass such normalisation by way of massively over-
sampling for most samples and targets. Thereby, despite
omitting quantification and normalisation, 98.6% of all
HLA amplicons achieved more than 100x on-target
coverage, which is sufficient for genotyping at the high-
est possible quality.
Sample repetition
On occasion, the initial genotyping attempt fails to meet
quality standards and the affected sample has to be reana-
lysed. This can affect either individual loci or the entire
sample. A full sample repeat typing including a second
DNA extraction is triggered if the initial DNA concentra-
tion is less than 2 ng/μl or more than 4 HLA loci fail to
produce credible results.
We can identify several common factors that may trig-
ger repeat typing of an individual locus: Technical con-
cerns include too low total read numbers, too few reads
on target, or heavy imbalances across alleles. Other causes
for concern are the presence of more alleles than ex-
pected, which might be a result of one or more of many
factors such as PCR chimerism, sample contamination,
co-amplification of closely related loci, misamplification
or sequencing errors. An analysis must also be repeated if
the genotyping software fails to construct a genotype. This
may occur for benign reasons (e.g., a novel allelic se-
quence is encountered) or be a result of stochastic allelic
dropouts during PCR [17]. More insidiously, allelic drop-
outs may remain “silent”, i.e., be technically valid but erro-
neous homozygous or even heterozygous genotypes may
arise [17]. Therefore, machine learning techniques are
employed to help identify “implausible” genotypes that
warrant repeated analyses to check their validity [17].
Whilst we strive to keep the rate of repetition low for
economic reasons, it is important to employ conserva-
tive quality thresholds and repetition criteria to achieve
the highest possible reliability of genotyping results. Re-
peat genotyping runs are automatically suggested by the
genotyping software based on conservative thresholds
for quality metrics and triggered manually after inspec-
tion of suspicious typing results [5]. In addition, analysts
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may trigger repeat typings for putative novel alleles and in
cases where genotypes suggested by the software are con-
sidered to be implausible (e.g., genotypes that have rarely
been encountered before in our sample populations).
Between January 2013 and November 2015 (Fluidigm
old workflow) a total of 3.6% of individual loci were re-
peated and a total of 4.4% of full samples were rerun.
Both locus and workflow heavily affect repetition rates.
Subjecting all samples to the Fluidigm workflow, HLA-
C, -DQB1, and -DPB1 showed high average repetition
rates around 4%, whilst HLA-A, -B, and -DRB1 showed
average repetition rates around 2% (Fig. 9). The intro-
duction of the 384 PCR workflow for low-concentration
samples in November 2015 had a marked twofold effect
on repetition rates. First, repetition rates decreased from
3.6 to 2.0% for individual loci and from 4.4 to 2.5% for
full samples for the high-concentration samples still
processed on Fluidigm chips. Such an improvement was
expected since problematic samples with low DNA con-
centrations were shifted to another workflow. Second,
and more unexpected, with 1.3% for individual loci and
2.5% for full samples repetition rates for the low-
concentration samples now processed with the 384 PCR
workflow were comparable to or lower than the repeti-
tion rates achieved for the high-concentration samples
on the Fluidigm chips (Figs. 9 and 10). This effect is
likely explained by the fact that low DNA concentrations
on Fluidigm Access Array chips adversely affect allelic
dropout rates [17]. Accordingly, we find that the likeli-
hood of a locus being repeated correlates inversely to
the initial template DNA concentration when using
Fluidigm chips whilst this relationship is markedly less
pronounced in the 384 PCR workflow (Fig. 10).
Novel alleles
Our in-house genotyping software classifies and reports
all consensus sequences differing from the reference al-
leles found in the IMGT/HLA database as potential novel
alleles. Given the likelihood of such signatures being gen-
erated by artefacts such as PCR errors, co-amplification
products, or noise, these samples need to be verified by re-
peat typing of an independent PCR product. Prior to 2015
this verification process was not performed automatically
but was left to a technician’s discretion. As of January
2015, all potential novel sequences routinely undergo re-
peat typing. For this reason, we restrict the analysis de-
scribed to samples typed between January 2015 and May
2016, for which data are exhaustive.
During this period of 17 months, a total of 17,184,548
HLA alleles from 1,432,944 donors were typed. In the
case of 13,835 (0.081%) alleles repeat typing was trig-
gered because the signature of a potential novel allele
was detected. 3,674 (26.4%) sequences could be con-
firmed as bona fide novel alleles, representing 1,919
unique novel sequences. In the remainder of the cases
repeated sequencing suggested that the initial deviation
from known alleles was caused by PCR or sequencing
artefacts. It follows that we observe a maximum PCR
error rate of 0.06%. A PCR error might mask a true
novel allele if the error actually restored the polymorph-
ism to the reference sequence. If we assume an average
length of 730 bp for an allelic sequence composed of
exons 2 and 3, we expect approximately one undetected
novel allele in 5 million bona fide novel alleles. Novel
alleles were not equally distributed amongst HLA loci.
Overall we found class II loci three-fold over-represented
amongst samples with novel alleles (2,816 class II loci vs.
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858 class I loci; Fig. 11; Table 2). Interestingly, however,
the rate of discovery of distinct novel sequences was far
smaller amongst class II loci compared to class I loci
(Class II: 40.5% unique novel sequence; Class I: 90.7%
unique novel sequences; Fig. 11).
Using these data we attempted to forecast the ex-
pected number of distinct novel alleles for the different
HLA loci. First we resampled the original 1.43 million
samples into 14 bins of 105 samples each. This resam-
pling procedure was repeated 30 times. Treating these
Fig. 10 Dependency between initial template DNA concentration and the number of HLA loci per donor that have to be verified in repeat
typing. Colours indicate different workflows (see Methods for detail). The point size is indicative of sample size
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bins as successive points in time (i.e., mimicking months
of routine typing) we estimated the rate of discovery of
distinct novel alleles at each of these successive sampling
points. The expected decrease in discovery rate was
modelled using a 3-parameter exponential decay model
(Additional file 5: Figure S4). The models for the differ-
ent loci were used to project the expected number of
novel distinct alleles at 3, 6, and 9 million typed samples,
respectively (Table 2).
It should be noted that these projections are subject to
two important limitations: first they presume no change
in the current ethnic make-up of donors processed at our
lab (mainly Caucasians) and, second, they concern only
novel alleles due to variation at exons 2 and 3 alone.
Given these restrictions, our estimates indicate that
HLA-A is expected to be saturated for novel alleles (at
exons 2 and 3) in the near future and that we can expect
that most undiscovered variation is still harboured in
class II loci, especially HLA-DQB1.
Discussion
In recent years it has been extensively demonstrated that
NGS can be applied to allele-level HLA typing with min-
imal ambiguity, providing benefits such as clonal se-
quencing to achieve in-phase reads and massive
parallelism to enable the expansion of the regions se-
quenced [5, 6, 18–24]. Many tissue typing laboratories,
however, have yet to fully embrace NGS technologies for
routine high-throughput operations. DKMS Life Science
Lab was one of the first labs to do so and has subsequently
accumulated three and a half years of experience with rou-
tine HLA typing using an amplicon-based approach on
the Illumina platforms. Over that period, more target
genes were added (CCR5, ABO, RHD, and KIR) and geno-
typing data for 2.7 Mio samples was retrieved from 3,642
MiSeq and HiSeq sequencing runs (Fig. 1).
The amplicon-based approach was initially chosen for
two major reasons. First, it is applicable to most genomic
loci with modest modifications both in the laboratory
workflow and the analysis software. This allowed rapidly
supplementing the standard HLA typing portfolio with
ABO, RHD, CCR5 and KIR typing as straightforward
extensions to the core HLA typing workflow [8]. Perhaps
equally important for production-scale operations is the
simplicity and robustness of a PCR-based approach. Most
steps in a PCR-based workflow can be automated using li-
quid handling robotic stations and high-throughput PCR
solutions such as the Fluidigm Access Array System or
high-capacity thermocyclers. Moreover, the amplicon-
based approach proved highly resilient to the wide range
of DNA quantities derived from the primary sources ma-
terial (Fig. 2), tolerating as little as 2 ng/μl initial template
DNA concentration (Fig. 7).
With our large-scale NGS HLA typing strategy we ob-
tained high-resolution genotype assignments for an average
of 98.9% of the HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1
loci typed (Table 1). The lowest high-resolution typing rate
was achieved for HLA-C (96.8%). HLA-C turned out to be
a challenging locus in many regards: In the Fluidigm
workflow, before the separation of low- and high-
DNA-concentration samples, it showed the highest
average primer dimer rate amongst all loci (32.8% ±
14.1% SD; Additional file 6: Figure S5) and, corres-
pondingly, the lowest average numbers of on-target
reads (Fig. 8). Exon 3 of HLA-C showed the highest
proportion of detected chimeric reads amongst all
amplicons (Fig. 6) and HLA-C is amongst the loci
with the highest average repetition rates (Fig. 9).
However, many of these issues resolved or improved
not only for HLA-C but also other loci when we started
to treat low-DNA-concentration samples (<18 ng/μl)
and high-DNA- concentration samples differently. Low
initial DNA concentrations in conjunction with the
nanolitre-scale reaction volumes on 192.24 Fluidigm Ac-
cess Array chips and the time- and cost-effective single-
PCR 4-primer approach caused problems that largely
dissipated once standard microlitre reaction volumes
and 2-primer PCR setups were used. Alternatively, nano-
fluidic chips could be used in combination with a con-
ventional 2-primer chemistry, which would probably
also resolve issues with primer dimers and PCR arte-
facts. It should also be noted that the sample repetition
rates reported arise from two main cases: a) truly failed
amplifications producing insufficient read depths for
Table 2 Novel alleles discovered between January 2015 and May 2016
Locus Samples Total novel alleles Distinct novel alleles Estimates of number of distinct novel alleles at n typed samples
3 M 6 M 9 M
HLA-A 1.43 M 248 230 315 393 394
HLA-B 1.43 M 325 293 431 688 921
HLA-C 1.43 M 285 255 391 697 1001
HLA-DRB1 1.43 M 1011 364 702 1254 1806
HLA-DQB1 1.43 M 941 464 830 1443 2055
HLA-DPB1 1.43 M 864 313 615 1088 1561
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genotyping and b) results that are largely correct, but
get flagged for repeat typing for verification purposes.
This includes rare alleles as well as results that may have
suffered from PCR drop out due to limited dilution. For
low DNA concentration samples applied to the 192
chips, that effect, although still rare, becomes measur-
able [18]. Therefore, these repeats reflect our extremely
high standards with regard to minimal error genotyping.
Whilst the Fluidigm workflow as originally devised [5]
has some operational advantages, such as being less com-
plex to automate and having low reagent costs, in our lab
it remains a viable option only for high-quality samples.
As the DNA concentration effects are relatively subtle,
they often only become possible to track down after a
large amount of data has accumulated. Thus, we now see
clear evidence that sequential 2-primer PCRs should be
preferred over 4-primer amplicon tagging workflows espe-
cially if increased formation of chimeric reads and primer
dimers pose a risk for the intended application. We also
suggest that proofreading polymerases should best be used
in conjunction with PTO primers unless it is assured that
exonuclease activity is effectively inhibited before heat ac-
tivation. Finally, when low template DNA concentrations
cannot be avoided for applications that are sensitive to
stochastic dropout of alleles, a standard PCR setup might
be a better fit than a nanofluidics platform.
Large-scale NGS-based typing of HLA in the context
of donor registries with tens of thousands of samples
processed each month requires substantial upfront in-
vestments in terms of laboratory automation, IT infra-
structure and data analysis capacity. At DKMS Life
Science Lab we currently employ 3 custom automatic
DNA extraction platforms with a total capacity of more
than 25,000 samples/week, 18 robotic liquid handlers, 3
hydrocyclers, 20 Fluidigm cyclers, and 3 HiSeq 2500 in-
struments for sequencing. On one HiSeq 2500 instru-
ment, up to 10,000 samples can be jointly sequenced
within 3 days using “Rapid Run Mode” and a dual flow
cell run. Data analysis is performed using custom soft-
ware [5], currently running on 320 Xeon processor cores
and requiring 1.1 TB of storage capacity per month to re-
tain FASTQ files and analysis data. However, for the more
common use case of HLA typing in a clinical setting or a
diagnostic lab, the requirements are typically much less
demanding. Example workflows suitable for low- to
medium-throughput HLA genotyping using NGS have
been discussed extensively in the literature [4, 18, 20].
The next step in HLA genotyping subsequent to a
NGS-based amplicon approach is promised by long-read
single molecule sequencing technologies such as offered
by sequencing systems by Pacific Biosciences (PacBio) or
Oxford Nanopore Technologies (ONT). Combined with
long-range PCR they hold the promise of efficient and
accurate haplotype sequencing over multiple kilobases,
thereby making available exon and intron sequences not
covered by the current approach. At present the clinical
impact of sequence information outside the peptide
binding groove remains unknown except for variations
encoding null alleles [25]. Once scalable HLA typing
workflows and analysis software become available for
these technologies, it would appear short-sighted to dis-
miss the clinical potential of fully characterised HLA al-
leles. However, whilst HLA typing is already feasible
with PacBio instruments [26, 27], the limited benefit for
donor search strategies seems not to justify the five-fold
higher sequencing costs in the registry context. An alter-
native to PacBio-based systems may be provided by ONT’s
high-throughput PromethION system which promises
HiSeq-like throughput rates (https://www2.nanoporetech.
com/products/specifications) but at the time of writing
has not yet been released to customers.
Conclusions
Although long-read sequencing platforms are likely to de-
liver the next revolution in HLA typing, they cannot at
present truly compete in terms of throughput and costs per
sample with the currently available widely applied and
proven short-read-based approaches. We expect amplicon-
based NGS typing workflows to remain, at least for the next
few years, as the workhorse in high-volume targeted typing
applications like HLA genotyping for donor registries. Our
experience after genotyping more than 2.7 million samples
confirms that the short-amplicon-based genotyping ap-
proach exhibits the robustness required for everyday rou-
tine high-throughput operation. In particular, compared to
Sanger sequencing, the NGS based approach has proven to
be by far more cost efficient, easier to handle and less error
prone. Taking advantage of these lessons learned will help
to further increase robustness and efficiency and raise
awareness for potential pitfalls, thereby minimising spuri-
ous genotyping results. NGS has revolutionised whole gen-
ome sequencing and is starting to have a tremendous
impact on targeted sequencing applications, enabling pro-
jects of a whole new scale and breadth.
Methods
Samples, DNA isolation and quantification
All donor samples analysed here were provided by
DKMS and other bone marrow donor centres between
January 2013 and June 2016. Primary source material was
either whole blood (18%) or two self-administered buccal
swabs per donor (82% of all samples). DNA was isolated
from 150 μl whole blood or a single buccal swab using the
magnetic-bead-based “chemagic DNA Blood Kit special”
or “chemagic DNA Buccal Swab kit special” (Perkin Elmer,
Baesweiler, Germany), respectively. DNA was eluted in
100 μl elution buffer (10 mM Tris-HCl pH8.0). DNA con-
centrations were measured by quantitative fluorescence
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staining (SYBR Green, Biozym, Hessisch Oldendorf,
Germany) using the TECAN infinite 200Pro (Tecan,
Männedorf, Switzerland) plate reader. Depending on
DNA concentrations, typing profile and the time frame,
distinct workflows were applied (see below). Samples with
concentrations lower than 2 ng/μl were generally excluded
from typing. Samples from DKMS-US have only been re-
cently subject to genotyping at the DKMS Life Science
Lab and were not included in analyses that compare sam-
ples of different provenance.
Amplicon design
Primers were designed to target the core HLA exons 2
and 3 of HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1 as de-
scribed in Lange et al. [5]. Additional primers were de-
signed to create amplicons spanning exons 2 and 3 to help
resolve phase of class I loci. Phasing amplicon sizes range
between 580 bp and 720 bp. ABO amplicons were de-
signed for exons 6 and 7 as described in Lang et al. [8].
The blood group locus RHD was amplified for exon 5 and
6 in conjunction with the highly homologous gene RHCE
as positive control for RHD negative samples. The CCR5
amplicon encloses a 32-bp deletion that confers high re-
sistance against HIV-1 acquisition when homozygous [28].
For presence/absence typing of KIR genes, amplicons
were designed for exons 4, 5 and 7. Amplicon sizes for
HLA (excluding the phasing amplicons), blood groups
and CCR5 range between 313 bp and 426 bp. PCR primer
sequences will be provided to researchers upon request.
PCR amplification
Until November 2015, all samples were processed on
48.48 Fluidigm Access Array chips (2,304 PCR reactions
per chip) or on 192.24 Fluidigm Access Array chips
(4,608 PCR reactions per chip; Fluidigm Corporation,
South San Francisco, USA) using a single-PCR 4-primer
protocol (detailed in Lange et al. [5]). These workflows
are henceforth both referred to as Fluidigm workflow.
As of 2015-11-20, samples with DNA concentrations
lower than 18 ng/μl have been processed with an alter-
native 2-PCR 2-primer workflow (henceforth referred to
as 384 PCR workflow). Samples with DNA concentra-
tions higher than 18 ng/μl have continued to be proc-
essed with the Fluidigm workflow.
Briefly, for the Fluidigm workflow amplicons for HLA,
ABO, RHD, and CCR5 are generated concurrently on
Access Array chips. A single multiplexed PCR setup in-
cludes pairs of inner primers with target-specific 3’-tails
and 5’-tails complementary to two outer primers carrying
molecular identifier (MID) sequences and adaptors for se-
quencing on Illumina MiSeq or HiSeq 2500 instruments.
The amplicons for KIR genes are generated separately on
384-well plates. The loading of the Access Arrays and the
384-well pipetting procedure are performed on TECAN
Evo instruments (Tecan, Männedorf, Switzerland). The
loading, thermocycling and harvesting of the Access
Arrays takes approximately 5 h.
Samples with low-concentrated DNA have an in-
creased risk of allelic dropout [17], increased primer
dimer formation (this paper) and decreased average per-
centage of bases > Q30 across entire MiSeq/HiSeq runs
(this paper). As of November 2015, we have therefore
been applying a separate workflow (384 PCR) to samples
with DNA concentrations <18 ng/μl. In this workflow all
loci are amplified in 11 multiplexed primary PCR reac-
tions in separate 384-well plates as detailed in Lang et
al. [8] for ABO typing. Thermocycling is performed in
hydrocyclers (LGC Genomics, Berlin, Germany) for ap-
proximately 2.5 h. Next, all amplicons of each sample are
combined using volumes appropriate to maintain a balance
of targeted amplicons using a CyBi-Well vario system
(Analytik Jena AG, Jena, Germany). The CyBi-Well vario
system is also used to setup a subsequent secondary PCR
reaction to elongate the amplicons with MIDs and sequen-
cing adapters for Illumina sequencing. Amplicon pooling,
secondary PCR setup and thermocycling last about 1 h.
Whilst the Fluidigm workflow has remained technic-
ally the same since November 2015, the introduction of
the 384 PCR workflow for low-concentration samples
changed the average DNA-concentration of samples
subjected to the Fluidigm workflow. To distinguish
between these cases, we refer to the Fluidigm workflow
before and after November 2015 as Fluidigm old and
Fluidigm new, respectively.
Amplicon pooling, purification and quantification
PCR products generated on the Access Array system are
pooled for post-PCR processing. Several of these pools
are subsequently combined in equimolar amounts based
on qPCR quantification for sequencing on MiSeq or
HiSeq 2500 instruments. Before August 2014, the DNA
concentration after PCR was not normalised per sample
prior to pooling for reasons of time efficiency and costs.
Potentially, this can lead to severely unequal read distri-
butions across samples. For the Fluidigm workflow, em-
pirical analysis of the dependency of final read yield
from initial DNA concentration allowed for introducing
a novel equilibration strategy in August 2014 that effect-
ively uses initial DNA concentrations for quantification-
free post-PCR normalisation (Fig. 7).
Purification of several amplicon pools is then performed
in parallel using SPRIselect Beads (Beckman Coulter, Brea,
USA) with a ratio of 0.6:1 beads to DNA with a subsequent
dilution step for quantification by qPCR. Pooling, purifica-
tion and dilution for qPCR quantification are performed on
Biomek instruments (Beckman Coulter, Brea, USA) within
70 min. For qPCR the Library Quant Illumina Kit (KAPA
Biosystems, Boston, USA) with standards in a range from
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0.2 fM to 20 pM was used on ECO Real-Time PCR cyclers
(Illumina, San Diego, USA) or ABI-StepOnePlus qPCR cy-
clers (Thermo Fisher, Carlsbad, USA), respectively. Quanti-
fication lasts approximately 1 h. Barcoded amplicons are
pooled separately for KIR and the other loci.
Library preparation and MiSeq/HiSeq runs
The purified and quantified amplicon pools are mixed in
equimolar amounts and prepared as recommended by
Illumina (Illumina, San Diego, USA). Libraries are loaded
at 6.5 pM to 8 pM onto MiSeq or HiSeq flow cells with
10% PhiX spiked in. Paired-end sequencing is performed
at 249, 251 or 260 cycles, respectively. On average, library
preparation takes 30 min for a MiSeq and approximately
60 min for a HiSeq library.
Data analysis
All routine genotyping was performed using the in-house
developed software neXtype as described elsewhere [5, 8].
For HLA and KIR typing the IMGT/HLA [29] and IPD/
KIR [30] databases were used as references, respectively.
For ABO and RHD typing a modified NCBI dbRBC data-
base [31] was used as a reference. For CCR5 the sequence
for the wildtype without deletion and a 32 bp deletion
variant were retrieved from NCBI as reference. The rate
of primer dimers is determined by computationally
scanning for Illumina adaptor sequences in the for-
ward or reverse reads.
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